Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia
Authors
Keywords
-
Journal
Expert Review of Hematology
Volume 15, Issue 8, Pages 671-684
Publisher
Informa UK Limited
Online
2022-08-19
DOI
10.1080/17474086.2022.2112565
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies
- (2022) Bilal Rah et al. Frontiers in Pharmacology
- Thrombocytopenic myelofibrosis (MF) patients previously treated with a JAK inhibitor in a phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) [MOMENTUM].
- (2022) Aaron Thomas Gerds et al. JOURNAL OF CLINICAL ONCOLOGY
- MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor.
- (2022) Ruben A. Mesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk-adjusted safety analysis of pacritinib (PAC) in patients (pts) with myelofibrosis (MF).
- (2022) Naveen Pemmaraju et al. JOURNAL OF CLINICAL ONCOLOGY
- Current Clinical Investigations in Myelofibrosis
- (2021) Sangeetha Venugopal et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- MPN-038: PACIFICA: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary or Secondary Myelofibrosis and Severe Thrombocytopenia
- (2021) John Mascarenhas et al. Clinical Lymphoma Myeloma & Leukemia
- Paradigm shift: combination BET and JAK inhibition in myelofibrosis
- (2021) John Mascarenhas et al. LEUKEMIA
- A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2)
- (2021) Nicola Vianelli et al. BLOOD
- The Impact of Pacritinib on Myelofibrosis Symptoms in Patients with Moderate and Severe Thrombocytopenia: A Retrospective Analysis of Patients in the Persist-2 Study
- (2021) Jeanne M. Palmer et al. BLOOD
- Safety Analysis of Pacritinib in Patients with Myelofibrosis and Severe Thrombocytopenia
- (2021) John Mascarenhas et al. BLOOD
- A Retrospective Head-to-Head Comparison between Pacritinib and Ruxolitinib in Patients with Myelofibrosis and Moderate to Severe Thrombocytopenia
- (2021) John Mascarenhas et al. BLOOD
- Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 – 100 × 109/L): Final Analysis of an Open-Label Phase 2 Study
- (2021) Moshe Talpaz et al. Clinical Lymphoma Myeloma & Leukemia
- Combined Drug Targeting of p53-dependent and -independent Pathways Depletes Myelofibrosis Hematopoietic Stem/Progenitor Cells
- (2021) Min Lu et al. LEUKEMIA
- Momelotinib is a highly potent inhibitor of FLT3-mutant AML
- (2021) Mohammad Azhar et al. Blood Advances
- Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
- (2020) Claire N. Harrison et al. AMERICAN JOURNAL OF HEMATOLOGY
- Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts
- (2020) Haifa Kathrin Al‐Ali et al. BRITISH JOURNAL OF HAEMATOLOGY
- The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication
- (2020) Bridget K. Marcellino et al. Clinical Lymphoma Myeloma & Leukemia
- Severe thrombocytopenia in myelofibrosis is more prevalent than previously reported
- (2020) Lucia Masarova et al. LEUKEMIA RESEARCH
- Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
- (2020) Moshe Talpaz et al. LEUKEMIA
- Fedratinib in myelofibrosis
- (2020) Ann Mullally et al. Blood Advances
- Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management
- (2020) Ayalew Tefferi AMERICAN JOURNAL OF HEMATOLOGY
- Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis
- (2020) Nils B. Leimkühler et al. Cell Stem Cell
- Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis
- (2020) Aaron T. Gerds et al. Blood Advances
- Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling
- (2019) Daniel A. C. Fisher et al. LEUKEMIA
- Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis
- (2018) Lucia Masarova et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes
- (2018) Mona M. Hosseini et al. LEUKEMIA
- The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
- (2018) Tiziano Barbui et al. Blood Cancer Journal
- Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
- (2018) Claire N Harrison et al. Lancet Haematology
- Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis
- (2018) John Mascarenhas et al. JAMA Oncology
- Understanding early TLR signaling through the Myddosome
- (2018) Katherine R. Balka et al. JOURNAL OF LEUKOCYTE BIOLOGY
- The molecular details of cytokine signalling via the JAK/STAT pathway
- (2018) Rhiannon Morris et al. PROTEIN SCIENCE
- Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy
- (2018) Jack W. Singer et al. Oncotarget
- EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis
- (2018) Alessandro M. Vannucchi et al. HAEMATOLOGICA
- SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
- (2017) Ruben A. Mesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs
- (2017) Allison H. Scotch et al. LEUKEMIA RESEARCH
- JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms
- (2017) Jennifer M. O'Sullivan et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
- (2017) Claire N Harrison et al. Lancet Haematology
- Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
- (2017) Ruben A Mesa et al. Lancet Haematology
- Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
- (2016) William Vainchenker et al. BLOOD
- The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype
- (2016) A. A. Basiorka et al. BLOOD
- Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey
- (2016) Ruben Mesa et al. BMC CANCER
- Abstract CT159: Investigation of the absorption, metabolism, excretion, and mass balance of [14C]-pacritinib in healthy subjects: a phase I study
- (2016) Suliman Al-Fayoumi et al. CANCER RESEARCH
- Comparative biomarker profiles of pacritinib, momelotinib, pexidartinib, and ruxolitinib using BioMAP Diversity PLUS panel
- (2016) S. Al-Fayoumi et al. EUROPEAN JOURNAL OF CANCER
- Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
- (2016) Srdan Verstovsek et al. Journal of Hematology & Oncology
- JAK2V617F allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy
- (2016) G Barosi et al. LEUKEMIA
- Myeloproliferative neoplasm patient symptom burden and quality of life: Evidence of significant impairment compared to controls
- (2015) Lesley A. Anderson et al. AMERICAN JOURNAL OF HEMATOLOGY
- Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
- (2015) R. S. Komrokji et al. BLOOD
- Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?
- (2015) R Tamari et al. BONE MARROW TRANSPLANTATION
- IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms
- (2015) Lukas F. Mager et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
- (2015) Animesh Pardanani et al. JAMA Oncology
- How common are myeloproliferative neoplasms? A systematic review and meta-analysis
- (2014) Glen J. Titmarsh et al. AMERICAN JOURNAL OF HEMATOLOGY
- Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
- (2013) Moshe Talpaz et al. Journal of Hematology & Oncology
- Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
- (2012) Robyn M. Emanuel et al. JOURNAL OF CLINICAL ONCOLOGY
- One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience
- (2012) Ayalew Tefferi et al. MAYO CLINIC PROCEEDINGS
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies
- (2011) S Hart et al. LEUKEMIA
- Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia
- (2011) S Hart et al. Blood Cancer Journal
- CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms
- (2010) J. W. Tyner et al. BLOOD
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
- (2010) A. Quintas-Cardama et al. BLOOD
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- What are RBC-transfusion-dependence and -independence?
- (2010) R.P. Gale et al. LEUKEMIA RESEARCH
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele
- (2009) P. Guglielmelli et al. BLOOD
- Clinical relevance of JAK2 (V617F) mutant allele burden
- (2009) F. Passamonti et al. HAEMATOLOGICA
- Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post–Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
- (2009) Constantine S. Tam et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now